Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 350

1.

Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Dreifuss JA, Griffin ML, Frost K, Fitzmaurice GM, Potter JS, Fiellin DA, Selzer J, Hatch-Maillette M, Sonne SC, Weiss RD.

Drug Alcohol Depend. 2013 Jul 1;131(1-2):112-8. doi: 10.1016/j.drugalcdep.2012.12.010. Epub 2013 Jan 18.

2.

Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W.

Arch Gen Psychiatry. 2011 Dec;68(12):1238-46. doi: 10.1001/archgenpsychiatry.2011.121. Epub 2011 Nov 7.

3.

Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.

McDermott KA, Griffin ML, Connery HS, Hilario EY, Fiellin DA, Fitzmaurice GM, Weiss RD.

J Clin Psychiatry. 2015 Feb;76(2):189-94. doi: 10.4088/JCP.14m09096.

4.

Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?

Weiss RD, Griffin ML, Potter JS, Dodd DR, Dreifuss JA, Connery HS, Carroll KM.

Drug Alcohol Depend. 2014 Jul 1;140:118-22. doi: 10.1016/j.drugalcdep.2014.04.005. Epub 2014 Apr 24.

5.

The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.

Nielsen S, Hillhouse M, Weiss RD, Mooney L, Sharpe Potter J, Lee J, Gourevitch MN, Ling W.

Am J Addict. 2014 Jul-Aug;23(4):343-8. doi: 10.1111/j.1521-0391.2013.12105.x. Epub 2013 Sep 24.

6.

The Prescription Opioid Addiction Treatment Study: What have we learned.

Weiss RD, Rao V.

Drug Alcohol Depend. 2017 Apr 1;173 Suppl 1:S48-S54. doi: 10.1016/j.drugalcdep.2016.12.001.

7.

Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study.

Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM, McDermott KA, Srisarajivakul EN, Dodd DR, Dreifuss JA, McHugh RK, Carroll KM.

Drug Alcohol Depend. 2015 May 1;150:112-9. doi: 10.1016/j.drugalcdep.2015.02.030. Epub 2015 Mar 6.

8.

The multi-site prescription opioid addiction treatment study: 18-month outcomes.

Potter JS, Dreifuss JA, Marino EN, Provost SE, Dodd DR, Rice LS, Fitzmaurice GM, Griffin ML, Weiss RD.

J Subst Abuse Treat. 2015 Jan;48(1):62-9. doi: 10.1016/j.jsat.2014.07.009. Epub 2014 Aug 2.

9.

Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.

Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N.

JAMA Psychiatry. 2017 Dec 1;74(12):1197-1205. doi: 10.1001/jamapsychiatry.2017.3206.

PMID:
29049469
10.

Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder.

Griffin ML, Dodd DR, Potter JS, Rice LS, Dickinson W, Sparenborg S, Weiss RD.

Am J Drug Alcohol Abuse. 2014 Mar;40(2):157-62. doi: 10.3109/00952990.2013.842241. Epub 2013 Nov 12.

11.

Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.

Stimolo C, Favero VD, Zecchinato G, Buson R, Cusin D, Pellachin P, Simonetto P.

Clin Drug Investig. 2010;30 Suppl 1:27-31. doi: 10.2165/11536030-000000000-00000.

PMID:
20450243
12.

Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.

Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD.

Drug Alcohol Depend. 2010 Mar 1;107(2-3):253-6. doi: 10.1016/j.drugalcdep.2009.10.014. Epub 2009 Nov 30.

13.

Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.

Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG.

JAMA Intern Med. 2014 Dec;174(12):1947-54. doi: 10.1001/jamainternmed.2014.5302.

PMID:
25330017
14.

A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.

Neumann AM, Blondell RD, Jaanimägi U, Giambrone AK, Homish GG, Lozano JR, Kowalik U, Azadfard M.

J Addict Dis. 2013;32(1):68-78. doi: 10.1080/10550887.2012.759872.

15.
16.

Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.

Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, Rota AG.

Clin Drug Investig. 2010;30 Suppl 1:21-6. doi: 10.2165/11536010-000000000-00000.

PMID:
20450242
17.

Using behavioral economics to predict opioid use during prescription opioid dependence treatment.

Worley MJ, Shoptaw SJ, Bickel WK, Ling W.

Drug Alcohol Depend. 2015 Mar 1;148:62-8. doi: 10.1016/j.drugalcdep.2014.12.018. Epub 2014 Dec 30.

18.

Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.

Becker WC, Ganoczy D, Fiellin DA, Bohnert AS.

J Subst Abuse Treat. 2015 Jan;48(1):128-31. doi: 10.1016/j.jsat.2014.09.007. Epub 2014 Sep 26.

PMID:
25312475
20.

Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.

Strain EC, Stoller K, Walsh SL, Bigelow GE.

Psychopharmacology (Berl). 2000 Mar;148(4):374-83.

PMID:
10928310

Supplemental Content

Support Center